Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2011 | 2 |
2013 | 1 |
2018 | 1 |
2020 | 1 |
2021 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Signatures of drug sensitivity in nonsmall cell lung cancer.
Int J Proteomics. 2011;2011:215496. doi: 10.1155/2011/215496. Epub 2011 Aug 7.
Int J Proteomics. 2011.
PMID: 22091388
Free PMC article.
Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS).
Wärnberg F, Karlsson P, Holmberg E, Sandelin K, Whitworth PW, Savala J, Barry T, Leesman G, Linke SP, Shivers SC, Vicini F, Shah C, Weinmann S, Mann GB, Bremer T.
Wärnberg F, et al. Among authors: leesman g.
Cancers (Basel). 2021 Dec 3;13(23):6103. doi: 10.3390/cancers13236103.
Cancers (Basel). 2021.
PMID: 34885211
Free PMC article.
Item in Clipboard
A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk.
Bremer T, Whitworth PW, Patel R, Savala J, Barry T, Lyle S, Leesman G, Linke SP, Jirström K, Zhou W, Amini RM, Wärnberg F.
Bremer T, et al. Among authors: leesman g.
Clin Cancer Res. 2018 Dec 1;24(23):5895-5901. doi: 10.1158/1078-0432.CCR-18-0842. Epub 2018 Jul 27.
Clin Cancer Res. 2018.
PMID: 30054280
Item in Clipboard
Validation of a Ductal Carcinoma In Situ Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy.
Weinmann S, Leo MC, Francisco M, Jenkins CL, Barry T, Leesman G, Linke SP, Whitworth PW, Patel R, Pellicane J, Wärnberg F, Bremer T.
Weinmann S, et al. Among authors: leesman g.
Clin Cancer Res. 2020 Aug 1;26(15):4054-4063. doi: 10.1158/1078-0432.CCR-19-1152. Epub 2020 Apr 27.
Clin Cancer Res. 2020.
PMID: 32341032
Item in Clipboard
A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers.
Lee J, Kim S, Kim P, Liu X, Lee T, Kim KM, Do IG, Park JO, Park SH, Jang J, Hoe N, Harvie G, Kuller A, Jain A, Meyer G, Leesman G, Park YS, Choi MG, Sohn TS, Bae JM, Lim HY, Singh S, Kang WK.
Lee J, et al. Among authors: leesman g.
PLoS One. 2013;8(1):e54644. doi: 10.1371/journal.pone.0054644. Epub 2013 Jan 25.
PLoS One. 2013.
PMID: 23372746
Free PMC article.
Item in Clipboard
Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients.
Kim P, Liu X, Lee T, Liu L, Barham R, Kirkland R, Leesman G, Kuller A, Ybarrondo B, Ng SC, Singh S.
Kim P, et al. Among authors: leesman g.
Proteome Sci. 2011 Dec 15;9(1):75. doi: 10.1186/1477-5956-9-75.
Proteome Sci. 2011.
PMID: 22172159
Free PMC article.
Item in Clipboard
Cite
Cite